Switch theme
Sign up to access all valuation multiples
TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.
1957
3.1K+
LTM Revenue $1.7B
LTM EBITDA $297M
$2.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
TOWA Pharmaceutical has a last 12-month revenue of $1.7B and a last 12-month EBITDA of $297M.
In the most recent fiscal year, TOWA Pharmaceutical achieved revenue of $1.5B and an EBITDA of $288M.
TOWA Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See TOWA Pharmaceutical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.5B | XXX | XXX | XXX |
| Gross Profit | $466M | $483M | XXX | XXX | XXX |
| Gross Margin | 34% | 32% | XXX | XXX | XXX |
| EBITDA | $164M | $288M | XXX | XXX | XXX |
| EBITDA Margin | 12% | 19% | XXX | XXX | XXX |
| Net Profit | $106M | $14.6M | XXX | XXX | XXX |
| Net Margin | 8% | 1% | XXX | XXX | XXX |
| Net Debt | $717M | $912M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, TOWA Pharmaceutical's stock price is JPY 2439 (or $16).
TOWA Pharmaceutical has current market cap of JPY 120B (or $798M), and EV of JPY 314B (or $2.1B).
See TOWA Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.1B | $798M | XXX | XXX | XXX | XXX | $2.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, TOWA Pharmaceutical has market cap of $798M and EV of $2.1B.
TOWA Pharmaceutical's trades at 1.2x LTM EV/Revenue multiple, and 7.0x LTM EBITDA.
Analysts estimate TOWA Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for TOWA Pharmaceutical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.1B | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | 7.1x | XXX | XXX | XXX |
| P/E | 7.5x | XXX | XXX | XXX |
| P/E/Growth | 3.5x | XXX | XXX | XXX |
| EV/FCF | -14.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTOWA Pharmaceutical's NTM/LTM revenue growth is 5%
TOWA Pharmaceutical's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, TOWA Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate TOWA Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for TOWA Pharmaceutical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 76% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 22% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 28% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TOWA Pharmaceutical acquired XXX companies to date.
Last acquisition by TOWA Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . TOWA Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was TOWA Pharmaceutical founded? | TOWA Pharmaceutical was founded in 1957. |
| Where is TOWA Pharmaceutical headquartered? | TOWA Pharmaceutical is headquartered in Japan. |
| How many employees does TOWA Pharmaceutical have? | As of today, TOWA Pharmaceutical has 3.1K+ employees. |
| Is TOWA Pharmaceutical publicy listed? | Yes, TOWA Pharmaceutical is a public company listed on TKS. |
| What is the stock symbol of TOWA Pharmaceutical? | TOWA Pharmaceutical trades under 4553 ticker. |
| When did TOWA Pharmaceutical go public? | TOWA Pharmaceutical went public in 2004. |
| Who are competitors of TOWA Pharmaceutical? | Similar companies to TOWA Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of TOWA Pharmaceutical? | TOWA Pharmaceutical's current market cap is $798M |
| What is the current revenue of TOWA Pharmaceutical? | TOWA Pharmaceutical's last 12-month revenue is $1.7B. |
| What is the current EBITDA of TOWA Pharmaceutical? | TOWA Pharmaceutical's last 12-month EBITDA is $297M. |
| What is the current EV/Revenue multiple of TOWA Pharmaceutical? | Current revenue multiple of TOWA Pharmaceutical is 1.2x. |
| What is the current EV/EBITDA multiple of TOWA Pharmaceutical? | Current EBITDA multiple of TOWA Pharmaceutical is 7.0x. |
| What is the current revenue growth of TOWA Pharmaceutical? | TOWA Pharmaceutical revenue growth between 2023 and 2024 was 9%. |
| Is TOWA Pharmaceutical profitable? | Yes, TOWA Pharmaceutical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
